Patents by Inventor Stan VAN BOECKEL

Stan VAN BOECKEL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cathepsin inhibitors
    Patent number: 11820734
    Abstract: This invention relates to compounds that are useful as inhibitors, in particular as inhibitors of Cathepsin K (CatK), and to a method of inhibiting cathepsin activity, comprising administering a compound or formulation comprising a compound according to the invention.
    Type: Grant
    Filed: October 20, 2021
    Date of Patent: November 21, 2023
    Assignee: ACADEMISCH ZIEKENHUIS LEIDEN (H.O.D.N. LUMC)
    Inventors: Huib Ovaa, Maria Wilhelmina Elisabeth Mons, Stan Van Boeckel
  • CATHEPSIN INHIBITORS
    Publication number: 20220227705
    Abstract: This invention relates to compounds that are useful as inhibitors, in particular as inhibitors of Cathepsin K (CatK), and to a method of inhibiting cathepsin activity, comprising administering a compound or formulation comprising a compound according to the invention.
    Type: Application
    Filed: October 20, 2021
    Publication date: July 21, 2022
    Applicant: ACADEMISCH ZIEKENHUIS LEIDEN (H.O.D.N. LUMC)
    Inventors: Huib OVAA, Maria Wilhelmina Elisabeth MONS, Stan VAN BOECKEL
  • Cathepsin inhibitors
    Patent number: 11174224
    Abstract: This invention relates to compounds that are useful as inhibitors, in particular as inhibitors of Cathepsin K (CatK), and to a method of inhibiting cathepsin activity, comprising administering a compound or formulation comprising a compound according to the invention.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: November 16, 2021
    Assignee: ACADEMISCH ZIEKENHUIS LEIDEN (H.O.D.N. LUMC)
    Inventors: Huib Ovaa, Maria Wilhelmina Elisabeth Mons, Stan Van Boeckel
  • CATHEPSIN INHIBITORS
    Publication number: 20200385341
    Abstract: This invention relates to compounds that are useful as inhibitors, in particular as inhibitors of Cathepsin K (CatK), and to a method of inhibiting cathepsin activity, comprising administering a compound or formulation comprising a compound according to the invention.
    Type: Application
    Filed: December 5, 2018
    Publication date: December 10, 2020
    Applicant: ACADEMISCH ZIEKENHUIS LEIDEN (H.O.D.N. LUMC)
    Inventors: Huib OVAA, Maria Wilhelmina Elisabeth MONS, Stan VAN BOECKEL
  • N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase
    Patent number: 10590082
    Abstract: Deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are N-alkylated D-galacto, D-gluco- or L-ido-deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bicyclic aromatic group (“X”) on the methyloxy-carbon. Formula (I), Formula (Ia). These compounds display an increased inhibitory potency towards GCS, and/or an increased inhibitory potency towards GBA2, and/or a decreased inhibitory potency towards GBA1, relative to known deoxynojirimycin derivatives of the same (D-gluco, L-ido or D-galacto) configuration.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: March 17, 2020
    Assignees: Academisch Medisch Centrum, Universiteit Leiden
    Inventors: Herman Steven Overkleeft, Stan Van Boeckel, Johannes Maria Franciscus Gerardus Aerts, Amar Ghisaidoobe, Richard Van Den Berg
  • N-(5-((ARYL OR HETEROARYL)METHYLOXY)PENTYL)-SUBSTITUTED IMINOSUGARS AS INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE
    Publication number: 20190144388
    Abstract: Deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are N-alkylated D-galacto, D-gluco- or L-ido-deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bicyclic aromatic group (“X”) on the methyloxy-carbon. Formula (I), Formula (Ia). These compounds display an increased inhibitory potency towards GCS, and/or an increased inhibitory potency towards GBA2, and/or a decreased inhibitory potency towards GBA1, relative to known deoxynojirimycin derivatives of the same (D-gluco, L-ido or D-galacto) configuration.
    Type: Application
    Filed: January 7, 2019
    Publication date: May 16, 2019
    Inventors: Herman Steven OVERKLEEFT, Stan VAN BOECKEL, Johannes Maria Franciscus Gerardus AERTS, Amar GHISAIDOOBE, Richard VAN DEN BERG
  • N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase
    Patent number: 10189784
    Abstract: Deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are N-alkylated D-galacto, D-gluco- or L-ido-deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bicyclic aromatic group (“X”) on the methyloxy-carbon. These compounds display an increased inhibitory potency towards GCS, and/or an increased inhibitory potency towards GBA2, and/or a decreased inhibitory potency towards GBA1, relative to known deoxynojirimycin derivatives of the same (D-gluco, L-ido or D-galacto) configuration.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: January 29, 2019
    Assignees: ACADEMISCH MEDISCH CENTRUM, UNIVERSITEIT LEIDEN
    Inventors: Herman Steven Overkleeft, Stan Van Boeckel, Johannes Maria Franciscus Gerardus Aerts, Amar Ghisaidoobe, Richard Van Den Berg
  • N-(5-((ARYL OR HETEROARYL)METHYLOXY)PENTYL)-SUBSTITUTED IMINOSUGARS AS INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE
    Publication number: 20170226058
    Abstract: Deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are N-alkylated D-galacto, D-gluco- or L-ido-deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bicyclic aromatic group (“X”) on the methyloxy-carbon. These compounds display an increased inhibitory potency towards GCS, and/or an increased inhibitory potency towards GBA2, and/or a decreased inhibitory potency towards GBA1, relative to known deoxynojirimycin derivatives of the same (D-gluco, L-ido or D-galacto) configuration.
    Type: Application
    Filed: March 23, 2015
    Publication date: August 10, 2017
    Inventors: Herman Steven OVERKLEEFT, Stan VAN BOECKEL, Johannes Maria Franciscus Gerardus AERTS, Amar GHISAIDOOBE, Richard VAN DEN BERG